Effect of subcutaneous recombinant human parathyroid hormone, rhPTH(1--84), on skeletal dynamics in hypoparathyroidism: findings from the 24-week replace and 8-week relay phase III clinical trials
Some cookies are essential and the website may not work correctly without them. These cookies can only be removed by changing your browser preferences.
Other cookies
We use tracking cookies and other non-essential cookies to help improve our services.
We place cookies on your device to give you the best experience of this website. If you don't change your cookie settings, we'll assume you're happy with this.